Can the morbidity of asthma be reduced by high doseinhaled therapy? A prospective study
| Autor: | C.R. Horn, T.J.H. Clark, G.M. Cochrane |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Agonist medicine.drug_class Peak Expiratory Flow Rate Airflow obstruction Forced Expiratory Volume Administration Inhalation Humans Medicine Albuterol Prospective Studies Prospective cohort study Asthma Community based business.industry Beclomethasone medicine.disease respiratory tract diseases High dosage Anesthesia Salbutamol Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Respiratory Medicine. 84:61-66 |
| ISSN: | 0954-6111 |
| DOI: | 10.1016/s0954-6111(08)80096-0 |
| Popis: | A community based, prospective study of the value of high dose inhaled therapy for the reduction of themorbidity of asthma has been undertaken. One hundred and sixty adults with airflow obstruction were treated for up to 9 months with increasing doses of salbutamol. Two thirds of the patients also received increasing doses of beclomethasone dipropionate in a ‘partially double-blind' manner. The FEV 1 rose by at least 10 per cent of that predicted in one third of the total patients and the overall meandomiciliary peak expiratory flow rates rose by approximately 501/min −1 . All chronic symptoms were abolished in half of the patients and acute attacks of asthma in the majority. Asthma was controlled in a greater proportion of patients more effectively and rapidly by a combination of inhaled steroids and beta agonist than by salbutamol alone, particularly when inhaled steroids were started in relatively high dosage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|